GH Research (GHRS) Projected to Post Earnings on Thursday

GH Research (NASDAQ:GHRS) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect GH Research to post earnings of ($0.29) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

GH Research Stock Performance

NASDAQ:GHRS opened at $15.42 on Tuesday. The firm has a 50-day simple moving average of $14.96 and a 200-day simple moving average of $14.07. GH Research has a one year low of $7.98 and a one year high of $19.51. The firm has a market cap of $802.30 million, a P/E ratio of -20.84 and a beta of 0.99.

Analysts Set New Price Targets

Several brokerages have issued reports on GHRS. HC Wainwright dropped their target price on GH Research from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Wall Street Zen cut GH Research from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Needham & Company LLC set a $29.00 target price on shares of GH Research in a report on Tuesday, January 6th. TD Cowen reissued a “buy” rating on shares of GH Research in a research report on Monday, January 5th. Finally, Guggenheim restated a “buy” rating and issued a $29.00 price target on shares of GH Research in a report on Monday, January 5th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.11.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Barclays PLC boosted its position in GH Research by 63.4% in the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after buying an additional 822 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of GH Research in the second quarter worth $79,000. HRT Financial LP purchased a new position in shares of GH Research during the fourth quarter worth $202,000. Finally, BNP Paribas Financial Markets lifted its position in GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares during the period. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.